Search Results

Displaying Results 1-2 of 2 "'XNCR'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

Jul 06, 2026, 11:19 ET A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

platform.Other publicly traded names across antibody-engineering, immune-engager, and platform-based discovery approaches include Xencor (NASDAQ: XNCR), CytomX Therapeutics (NASDAQ: CTMX), Zymeworks (NASDAQ: ZYME), and Nurix Therapeutics (NASDAQ: NRIX), each distinct, and none a proxy

More news about: American News Group

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

Oct 17, 2025, 09:50 ET Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

GTBP), Evaxion A/S (NASDAQ: EVAX), RenovoRX, Inc. (NASDAQ:RNXT), EDAP TMS S.A. (NASDAQ: EDAP), and Xencor, Inc. (NASDAQ: XNCR).

More news about: Equity Insider

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.